Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX-042 in Cardiorenal Syndrome
NCT03019653Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2017
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of asbnp.1 in cardiorenal syndrome (CRS) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Change in Glomerular Filtration Rate at 3 weeks. Started Jan 2017; status: completed.
02
Drugs
asbnp.1
03
Conditions
cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NCT03019653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019653.